| Not Yet Recruiting | SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinom NCT06822010 | Rutgers, The State University of New Jersey | Phase 2 |
| Not Yet Recruiting | Neoadjuvent Dose-dense Gemcitabine and Cisplatin In Muscle Invasive Bladder Cancer NCT07184021 | Assiut University | Phase 2 |
| Recruiting | Association of POCD With Circulating Biomarkers in Patients Undergoing TUR of Bladder Tumor NCT07165236 | Osijek University Hospital | — |
| Not Yet Recruiting | Predictive Role of Microbiome in Patients With Urothelial Carcinoma NCT06675656 | IRCCS San Raffaele | — |
| Completed | Enhanced Assistance During Radiotherapy for Unmet Essential Needs NCT06582849 | Washington University School of Medicine | N/A |
| Completed | Histopathological Findings in En-Bloc vs Conventional Transurethral Resection of Bladder Tumors. NCT07259798 | Ain Shams University | N/A |
| Active Not Recruiting | Lung US for PEEP Optimization in Robotic Radical Prostatectomy or Cystectomy Patients NCT06307704 | Nazmy Edward Seif | N/A |
| Unknown | Role of MRI in Assessment of the Urinary Bladder Wall Post Transurethral Tumor Resection NCT05787938 | Assiut University | — |
| Recruiting | Intravesical Gem/Doce in Patients With NMIBC NCT05644041 | University of Arizona | Phase 2 |
| Active Not Recruiting | Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Inva NCT05822934 | Assiut University | Phase 3 |
| Withdrawn | Longitudinal Geriatric Assessment to Optimize Outcomes of Older Patients With Muscle-Invasive Bladder Cancer A NCT05335707 | University of Kansas Medical Center | — |
| Recruiting | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy NCT05621837 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | — |
| Recruiting | Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder NCT05072600 | Peking University First Hospital | Phase 2 |
| Recruiting | Neoadjuvant Toripalimab in Combination with Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer NCT04861584 | Zhujiang Hospital | Phase 2 |
| Unknown | Role of Hypofractionated Radiotherapy With Concurrent Gemcitabine in Treatment of Urinary Bladder Carcinoma NCT04812145 | Assiut University | — |
| Unknown | Multimodal Spectroscopy to Detect Urothelial Cancer in Urine NCT04718948 | University of Florence | — |
| Completed | Patterns of Urinary Bladder Cancer in Darfur, Suda NCT06156787 | National Center for Gastroentestinal and Liver Disease | — |
| Unknown | Clinicoepidimiological Study and Clinical Outcome in Patients With Urinary Bladder Cancer NCT04525781 | Assiut University | — |
| Completed | An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients. NCT03433924 | AstraZeneca | — |
| Completed | Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer NCT05946369 | Ain Shams University | — |
| Completed | Physical Rehabilitation Among Patients Undergoing Radical Cystectomy Due to Urinary Bladder Cancer NCT03998579 | Karolinska Institutet | N/A |
| Terminated | Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Tre NCT03335059 | Medical Enterprises Ltd. | Phase 3 |
| Completed | Evaluation of NanoDoce® in Participants With Urothelial Carcinoma NCT03636256 | NanOlogy, LLC | Phase 1 / Phase 2 |
| Completed | Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute NCT04635566 | Mansoura University | N/A |
| Unknown | Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder NCT03529890 | Technical University of Munich | Phase 2 |
| Recruiting | A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and N NCT03844256 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 1 / Phase 2 |
| Active Not Recruiting | MAGE-A4ᶜ¹º³²T for Multi-Tumor NCT03132922 | Adaptimmune | Phase 1 |
| Completed | A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer NCT02897765 | BioNTech US Inc. | Phase 1 |
| Completed | Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer NCT02722538 | Taris Biomedical LLC | Phase 1 |
| Completed | Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer NCT02720367 | Taris Biomedical LLC | Phase 1 |
| Completed | Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomo NCT02437539 | Rigshospitalet, Denmark | Phase 1 |
| Unknown | Comparing Operative, Postoperative and Quality of Life of Patients After Salvage and Radical Cystectomy NCT06115434 | Assiut University | — |
| Completed | Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomo NCT02139371 | Rigshospitalet, Denmark | EARLY_Phase 1 |
| Completed | Prehabilitation to Enhance Postoperative Functional Capacity Following Radical Cystectomy NCT01836978 | McGill University Health Centre/Research Institute of the McGill University Health Centre | N/A |
| Terminated | PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer NCT01374789 | WiSP Wissenschaftlicher Service Pharma GmbH | Phase 2 |
| Completed | Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ NCT00462488 | Sesen Bio, Inc. | Phase 2 |
| Recruiting | Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer NCT00872495 | Lahey Clinic | — |
| Terminated | Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for NCT00384891 | Medical Enterprises Europe B.V. | Phase 3 |